TY - JOUR
T1 - Targeted therapy for brain tumours
AU - Lesniak, Maciej S.
AU - Brem, Henry
N1 - Funding Information:
The research presented in this work has been supported in part by the National Cooperative Drug Discovery Group of the National Cancer Institute.
PY - 2004/6
Y1 - 2004/6
N2 - Although previously considered untreatable, brain tumours no longer carry the same prognosis as they did even a decade ago. Recent advances in drug delivery to the central nervous system have not only bypassed physiological constraints such as the blood-brain barrier, but have, in fact, changed the course of treatment for patients with malignant brain tumours. The creation of targeted therapies, which spare normal tissue and destroy tumour cells, is changing the field of neuro-oncology. In this article, we review recent developments in the delivery of drugs to tumours of the central nervous system, discuss current trends and directions in the development of novel drugs and delivery systems, and present new and cutting-edge strategies for overcoming the challenges ahead.
AB - Although previously considered untreatable, brain tumours no longer carry the same prognosis as they did even a decade ago. Recent advances in drug delivery to the central nervous system have not only bypassed physiological constraints such as the blood-brain barrier, but have, in fact, changed the course of treatment for patients with malignant brain tumours. The creation of targeted therapies, which spare normal tissue and destroy tumour cells, is changing the field of neuro-oncology. In this article, we review recent developments in the delivery of drugs to tumours of the central nervous system, discuss current trends and directions in the development of novel drugs and delivery systems, and present new and cutting-edge strategies for overcoming the challenges ahead.
UR - http://www.scopus.com/inward/record.url?scp=3042542580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042542580&partnerID=8YFLogxK
U2 - 10.1038/nrd1414
DO - 10.1038/nrd1414
M3 - Review article
C2 - 15173839
AN - SCOPUS:3042542580
SN - 1474-1776
VL - 3
SP - 499
EP - 508
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 6
ER -